Suchen
Unicycive Therapeutics Inc
UNCYZur Watchlist hinzufügen
8.260USD
-0.300-3.50%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
220.54MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Unicycive Therapeutics Inc Unternehmen
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Inc Informationen
BörsenkürzelUNCY
Name des UnternehmensUnicycive Therapeutics Inc
IPO-datumJun 17, 2021
CEOGupta (Shalabh)
Anzahl der mitarbeiter22
WertpapierartOrdinary Share
GeschäftsjahresendeJun 17
Addresse4300 El Camino Real, Suite 210
StadtLOS ALTOS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94022
Telefon16503840642
Websitehttps://unicycive.com/
BörsenkürzelUNCY
IPO-datumJun 17, 2021
CEOGupta (Shalabh)
Führungskräfte von Unicycive Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Vivo Capital, LLC
6.70%
Millennium Management LLC
4.39%
Octagon Capital Advisors LP
3.75%
Nantahala Capital Management, LLC
3.52%
Vanguard Capital Management, LLC
3.04%
Andere
78.60%
Aktionäre
Aktionäre
Anteil
Vivo Capital, LLC
6.70%
Millennium Management LLC
4.39%
Octagon Capital Advisors LP
3.75%
Nantahala Capital Management, LLC
3.52%
Vanguard Capital Management, LLC
3.04%
Andere
78.60%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
16.98%
Venture Capital
8.61%
Investment Advisor
4.70%
Individual Investor
2.36%
Investment Advisor/Hedge Fund
1.76%
Research Firm
0.54%
Pension Fund
0.29%
Andere
64.76%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
75
9.56M
35.81%
+450.87K
2025Q4
65
6.67M
31.03%
-253.32K
2025Q3
61
5.54M
31.38%
-1.91M
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Vivo Capital, LLC
1.79M
7.09%
--
--
Dec 31, 2025
Millennium Management LLC
1.17M
4.65%
+157.82K
+15.55%
Jan 16, 2026
Octagon Capital Advisors LP
1.00M
3.96%
--
--
Dec 31, 2025
Nantahala Capital Management, LLC
939.20K
3.72%
--
--
Dec 31, 2025
Great Point Partners, LLC
796.56K
3.16%
--
--
Dec 31, 2025
Gupta (Shalabh K)
597.25K
2.37%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
473.56K
1.88%
--
--
Dec 31, 2025
Citadel Advisors LLC
258.30K
1.02%
+216.63K
+519.81%
Dec 31, 2025
Rosalind Advisors, Inc.
242.49K
0.96%
+242.49K
--
Apr 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Jun 17, 2025
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Jun 17, 2025
Merger
10→1
